Core Viewpoint - The company, Stone Pharmaceutical Group, has received FDA approval for its monoclonal antibody JMT206, allowing it to conduct clinical trials in the U.S. This product has also been approved by the National Medical Products Administration of China for clinical trials starting in November 2025 [1]. Group 1 - The product JMT206 specifically binds to Activin Receptor IIA and IIB, blocking the interaction of Activin A, GDF8, and GDF11 with Activin Receptor IIB, thereby inhibiting downstream signaling pathways that lead to muscle loss [1]. - JMT206 aims to reduce muscle loss and promote skeletal muscle maintenance and growth, achieving a dual effect of muscle gain and fat loss [1]. - The clinical indication for JMT206 is weight management in obese or overweight individuals with at least one weight-related comorbidity [1]. Group 2 - Preclinical studies have demonstrated that JMT206 exhibits high bioavailability, along with good efficacy and safety, indicating significant clinical development value [1].
石药集团(01093)：重组全人源抗ACTRIIA / IIB单克隆抗体(JMT206) 在美国获临床试验批准